A recent study by Frenkel, Gazdar and colleagues concluded that depsipeptide co-administered with EGFR inhibitors gave a substantial advantage over EGFR inhibitors alone in xenograft models of lung cancer (Zhang et al, 2009). Here, EGFR is linked to lung cancer.